Parabilis Medicines, Inc. PBLS
Set alert
At close · Oct 30
After hours · Oct 30, 4:23 PM ET
- YTD
- -10.38%
- 1 year
- -10.38%
- Open
- 28.59
- Prev close
- 28.70
- Mkt cap
- 3.50B
- Vol
- 813.97K
- Avg vol
- 886.16K
- EPS
- -9.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 27.48
- High
- 28.74
- Forward P/E
- -12.95
- Beta
- 0.00
- Short ratio
- 7.03
- Inst. own
- 82.48%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 12, 2026
- 50-d avg
- 33.18
- 200-d avg
- 32.26
- 1y target
- 41.40
5D chart
Signals (107)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:50 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:55 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:55 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:10 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:45 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:30 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:40 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 1:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:30 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 12:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:05 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:35 AM | 6 days ago |
News
5 days ago seekingalpha.com
Parabilis Medicines: Bullish On Zolucatetide's Broad Oncology Potential
Zolucatetide gives PBLS potential in desmoid tumors, but it also has other Wnt-driven indications that could grow its TAM over time. PBLS's PEDESTAL trial is now a clearer R&D path, as long as early…
6 days ago seekingalpha.com
Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
Parabilis Medicines, Inc. (PBLS) Discusses Updated Zolucatetide Data in Desmoid Tumors and Phase III Path Transcript
1 week ago marketbeat.com
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
Parabilis Medicines NASDAQ: PBLS presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society for Medical Oncology…
1 week ago globenewswire.com
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with…
-
1 week ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $40
HC Wainwright & Co. initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $40.
1 week ago seekingalpha.com
Parabilis: $1B+ Rare-Disease Foundation Leaves The Big Oncology Pipeline For Free
Parabilis Medicines, Inc. is rated a speculative Buy due to its innovative peptide platform and strong rare-disease oncology pipeline. Lead asset zolucatetide (zolu) shows robust early efficacy in…
1 week ago benzinga.com
Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday
U.S. stocks mixed as Dow fell ~100 points; Silence Therapeutics surged 125.7% on Merck KGaA buyout, while biotech and tech shares gained.
-
1 week ago benzinga.com
Parabilis Medicines To Present Updated Clinical Data For Zolucatetide In Patients With Desmoid Tumors At ESMO Congress 2026
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid…
1 week ago globenewswire.com
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Oral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid…
-
2 weeks ago benzinga.com
Parabilis Medicines Initiates Dose-Ranging Clinical Cohort Evaluating Zolucatetide In Patients With Familial Adenomatous Polyposis As Part Of Ongoing Phase 1/2 Clinical Trial
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumorsZolucatetide directly inhibits β-catenin:TCF,…
2 weeks ago globenewswire.com
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors
1 month ago defenseworld.net
Parabilis Medicines (NASDAQ:PBLS) Shares Gap Up – Here’s What Happened
Parabilis Medicines, Inc. (NASDAQ: PBLS - Get Free Report)'s stock price gapped up prior to trading on Tuesday. The stock had previously closed at $31.20, but opened at $32.84. Parabilis Medicines…
1 month ago benzinga.com
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
1 month ago seekingalpha.com
Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Parabilis Medicines, Inc. (PBLS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago globenewswire.com
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with…
2 months ago globenewswire.com
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D.
CAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with…
2 months ago seekingalpha.com
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform
Parabilis Medicines (PBLS) leverages rare, genetically simple tumors to validate its Helicon platform, aiming for broader oncology applications. PBLS holds $1.1 billion in cash, providing a runway…
-
2 months ago benzinga.com
Parabilis Medicines Q2 EPS $(2.32) Misses $(0.08) Estimate, Sales $148.000K Miss $25.000M Estimate
Parabilis Medicines (NASDAQ:PBLS) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(0.08) by 2800 percent. This is a 89.59 percent increase over losses…
2 months ago globenewswire.com
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors
3 months ago 247wallst.com
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More
Pre-Market Stock Futures: Futures are trading mixed as we get ready to start the first full week of trading for the third quarter, as traders and investors return from the long 4th of July holiday.…
-
3 months ago benzinga.com
Leerink Partners Initiates Coverage On Parabilis Medicines with Outperform Rating, Announces Price Target of $40
Leerink Partners analyst Andrew Berens initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Outperform rating and announces Price Target of $40.
3 months ago benzinga.com
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
3 months ago benzinga.com
This Parabilis Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed outlook on top stocks. See full analyst rating changes & buy/sell recommendations for PBLS stock on Benzinga.
-
3 months ago benzinga.com
B of A Securities Initiates Coverage On Parabilis Medicines with Buy Rating, Announces Price Target of $45
B of A Securities analyst Tazeen Ahmad initiates coverage on Parabilis Medicines (NASDAQ:PBLS) with a Buy rating and announces Price Target of $45.
4 months ago fool.com
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
Parabilis saw its shares rise by more than SpaceX's shares did after its IPO. That doesn't mean it's guaranteed to succeed.
4 months ago fool.com
Fresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?
Director Alan Sebulsky acquired 17,500 shares for $474,000, based on a weighted average purchase price of $27.06 per share. This activity increased his ownership to 30,000 shares, held through an…
4 months ago globenewswire.com
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines…
4 months ago globenewswire.com
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biopharmaceutical company built to develop transformative medicines…
4 months ago reuters.com
Parabilis Medicines aims to raise $633 million in upsized US IPO
Biopharmaceutical company Parabilis Medicines said on Tuesday it was aiming to raise as much as $633.3 million in its upsized initial public offering in the U.S.